Overview
Enterra Medical develops and sells the Enterra Therapy system, a gastric electrical stimulation device used to treat drug-refractory gastroparesis. The system uses a small implantable neurostimulator in the lower abdomen and two leads placed in the stomach wall to deliver mild electrical pulses that help reduce nausea and vomiting, with stimulation adjusted by a physician and reversible if needed. Enterra Medical operates independently with Medtronic as an operational partner, continuing development like the Enterra II MR Conditional system and the newer Enterra ReliaStim lead to improve placement and MRI compatibility. The goal is to improve quality of life for patients with gastroparesis by providing a safe, adjustable, and reversible therapy when diet and medications have failed, and to expand applicable indications through ongoing research.
Work here?Claim your company
Simplify's take
What believers are saying
- FDA says Enterra Ascent may ship under enforcement policy while review continues.
- FDA 2026 PAC review found no new safety signals across 182 MDRs.
- Enterra ReliaStim and NAVIGATE broaden the product story beyond a single indication.
What critics are saying
- Enterra II shortages forced an availability interruption; hospitals face mid-November 2026 rationing.
- FDA still has not approved Enterra Ascent, so a review failure could halt sales.
- Gastroparesis remains a narrow HDE market; reimbursement setbacks could crush adoption and cash generation.
What makes Enterra Medical unique
- Enterra owns the only FDA-recognized GES franchise for refractory gastroparesis in 2026.
- Enterra ReliaStim, launched January 2026, improves lead placement precision and procedural consistency.
- Enterra Ascent keeps the installed-base therapy alive despite Enterra II component shortages.
Help us improve and share your feedback! Did you find this helpful?